Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population

References

• Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011;63(2):437–459. doi:10.1124/pr.110.003533
   PubMed Web of Science ®Google Scholar
• Wang L, Aikemu A, Yibulayin A, et al. Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China. BMC Genet. 2015;16(1):66. doi:10.1186/s12863-015-0232-x
   Web of Science ®Google Scholar
• Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350. doi:10.1038/nature15817
   PubMed Web of Science ®Google Scholar
• Jin T, Zhao R, Shi X, et al. Genetic polymorphisms study of pharmacogenomic VIP variants in Han ethnic of China’s Shaanxi province. Environ Toxicol Pharmacol. 2016;46:27–35. doi:10.1016/j.etap.2016.06.026
   Web of Science ®Google Scholar
• Evans WE, McLeod HL. Pharmacogenomics–drug disposition, drug targets, and side effects. N Engl J Med. 2003;348(6):538–549. doi:10.1056/NEJMra020526
   PubMed Web of Science ®Google Scholar
• Cheng Y, Dai R, Chen W, Li Q, Zhang C, Yang T. Genetic polymorphisms of pharmacogenomic VIP variants in the Dai population from Yunnan province. Mol Genet Genomic Med. 2020;8(7):e1231. doi:10.1002/mgg3.1231
   Web of Science ®Google Scholar
• Wang J, Chen Q, Wang L, et al. Identifying novel mutations of NKX2-5 congenital heart disease patients of Chinese minority groups. Int J Cardiol. 2011;148(1):102–104. doi:10.1016/j.ijcard.2010.05.041
   Web of Science ®Google Scholar
• Yi X, Liang Y, Huerta-Sanchez E, et al. Sequencing of 50 human exomes reveals adaptation to high altitude. Science. 2010;329(5987):75–78. doi:10.1126/science.1190371
   PubMed Web of Science ®Google Scholar
• Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protocol Hum Gene. 2009;60(1):12. doi:10.1002/0471142905.hg0212s60
   Google Scholar
• He Y, Yang H, Geng T, et al. Genetic polymorphisms of pharmacogenomic VIP variants in the lhoba population of southwest China. Int J Clin Exp Pathol. 2015;8(10):13293–13303.
   PubMed Web of Science ®Google Scholar
• Jin T, Yang H, Zhang J, et al. Polymorphisms and phenotypic analysis of cytochrome P450 3A4 in the Uygur population in northwest China. Int J Clin Exp Pathol. 2015;8(6):7083–7091.
   PubMed Web of Science ®Google Scholar
• Richard A. Gibbs, John W Belmont, Paul Hardenbol, et al. The International HapMap Project. Nature. 2003;426(6968):789–796. doi:10.1038/nature02168
   PubMed Web of Science ®Google Scholar
• Song MK, Lin FC, Ward SE, Fine JP. Composite variables: when and how. Nurs Res. 2013;62(1):45–49. doi:10.1097/NNR.0b013e3182741948
   PubMed Web of Science ®Google Scholar
• Burrell LM, Harrap SB, Velkoska E, Patel SK. The ACE2 gene: its potential as a functional candidate for cardiovascular disease. Clin Sci. 2013;124(2):65–76. doi:10.1042/cs20120269
   PubMed Web of Science ®Google Scholar
• Probstfield JL, O’Brien KD. Progression of cardiovascular damage: the role of renin-angiotensin system blockade. Am J Cardiol. 2010;105(1Suppl):10a–20a. doi:10.1016/j.amjcard.2009.10.006
   Google Scholar
• Jiang F, Yang J, Zhang Y, et al. Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets. Nat Rev Cardiol. 2014;11(7):413–426. doi:10.1038/nrcardio.2014.59
   PubMed Web of Science ®Google Scholar
• Magrone T, Magrone M, Jirillo E. Focus on receptors for coronaviruses with special reference to angiotensin- Converting enzyme 2 as a potential drug target - A perspective. Endocr Metab Immune Disord Drug Targets. 2020;20(6):807–811. doi:10.2174/1871530320666200427112902
   PubMed Web of Science ®Google Scholar
• Zhang Q, Cong M, Wang N, et al. Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender: a case-control study. Medicine. 2018;97(42):e12917. doi:10.1097/md.0000000000012917
   Web of Science ®Google Scholar
• Fan Z, Wu G, Yue M, et al. Hypertension and hypertensive left ventricular hypertrophy are associated with ACE2 genetic polymorphism. Life Sci. 2019;225:39–45. doi:10.1016/j.lfs.2019.03.059
   PubMed Web of Science ®Google Scholar
• Martínez-Rodríguez N, Posadas-Romero C, Villarreal-Molina T, et al. Single nucleotide polymorphisms of the angiotensin-converting enzyme (ACE) gene are associated with essential hypertension and increased ACE enzyme levels in Mexican individuals. PLoS One. 2013;8(5):e65700. doi:10.1371/journal.pone.0065700
   Web of Science ®Google Scholar
• de Oliveira FF, Chen ES, Smith MC, Bertolucci PHF. Pharmacogenetics of angiotensin-converting enzyme inhibitors in patients with Alzheimer’s disease dementia. Curr Alzheimer Res. 2018;15(4):386–398. doi:10.2174/1567205014666171016101816
   Web of Science ®Google Scholar
• Ferreira de Oliveira F, Berretta JM, Suchi CE, Cardoso SM, Ferreira BPH. Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease. Colomb Med. 2016;47(2):76–80. doi:10.25100/cm.v47i2.2188
   Web of Science ®Google Scholar
• Lee JY, Vinayagamoorthy N, Han K, et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2016;68(1):184–190. doi:10.1002/art.39402
   Web of Science ®Google Scholar
• López-García MA, Feria-Romero IA, Serrano H, et al. Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy. Pharmacol Rep. 2017;69(3):504–511. doi:10.1016/j.pharep.2017.01.007
   PubMed Web of Science ®Google Scholar
• Dlouhá L, Adámková V, Šedová L, Olišarová V, Hubáček JA, Tóthová V. Five genetic polymorphisms of cytochrome P450 enzymes in the Czech non-Roma and Czech Roma population samples. Drug Metab Pers Ther. 2020. doi:10.1515/dmdi-2020-0103
   Google Scholar
• Zhang C, Jiang X, Chen W, et al. Population genetic difference of pharmacogenomic VIP gene variants in the Lisu population from Yunnan Province. Medicine. 2018;97(52):e13674. doi:10.1097/md.0000000000013674
   Web of Science ®Google Scholar
• Yee SW, Gong L, Badagnani I, Giacomini KM, Klein TE, Altman RB. SLC19A1 pharmacogenomics summary. Pharmacogenet Genomics. 2010;20(11):708–715. doi:10.107/FPC.0b013e32833eca92
   Google Scholar
• Chatzikyriakidou A, Vakalis KV, Kolaitis N, et al. Distinct association of SLC19A1 polymorphism −43T>C with red cell folate levels and of MTHFR polymorphism 677C>T with plasma folate levels. Clin Biochem. 2008;41(3):174–176. doi:10.1016/j.clinbiochem.2007.11.006
   Web of Science ®Google Scholar
• Zhang X, Zhang D, Huang L, et al. Discovery of novel biomarkers of therapeutic responses in han chinese pemetrexed-based treated advanced NSCLC patients. Front Pharmacol. 2019;10:944. doi:10.3389/fphar.2019.00944
   Web of Science ®Google Scholar
• Wang S-M, Sun L-L, Zeng W-X, Wu W-S, Zhang G-L. Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia. Med Oncol. 2014;31(7):62. doi:10.1007/s12032-014-0062-0
   PubMed Web of Science ®Google Scholar